Viberzi label

Viberzi

Viberzi Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no side effect or adverse reaction information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

There is current no usage information for this drug.

History

There is currently no drug history available for this drug.

Other Information

There is currently no other information available for this drug.

Viberzi Manufacturers

  • Actavis Pharma, Inc
    Viberzi | Actavis Pharma, Inc
    No Recall

    Viberzi | Actavis Pharma, Inc

    Viberzi | Actavis Pharma, Inc

    The recommended dosage of VIBERZI is 100 mg taken orally twice daily with food.

    The recommended dosage of VIBERZI is 75 mg taken orally twice daily with food in patients who:

    do not have a gallbladder [see Warnings and Precautions (5.1), Adverse Reactions (6.1)]. are unable to tolerate the 100 mg dose of VIBERZI [see Adverse Reactions (6.1)]. are receiving concomitant OATP1B1 inhibitors [see Drug Interactions (7)]. have mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment [see Use in Specific Population (8.6), Clinical Pharmacology (12.3)].

    Discontinue VIBERZI in patients who develop severe constipation for more than 4 days.

    Instruct patients if they miss a dose, take the next dose at the regular time and not to take 2 doses at the same time to make up for a missed dose.